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Abstract
Only limited data are available on the development of neutralizing antibodies (NAB) in patients with chronic hepatitis C (CHC) treated
with pegylated interferon-a (PEG-IFN-a). The aim of this study was to evaluate the immunogenicity of PEG-IFN-a when administered to
CHC patients who had or had not previously received standard IFN-a therapy. In addition, the speciﬁcities of NAB, together with the abil-
ity of leucocyte (LE) -IFN-a to re-establish therapeutic responsiveness in NAB-positive patients, were evaluated. NAB were assessed using
a quantitative, standardized, virus-induced cytopathic effect assay. The seroconversion rate to PEG-IFN-a was higher in patients who had
received previous standard IFN-a treatment than in those treated exclusively with PEG-IFN-a. Also, NAB produced during PEG-IFN-a
therapy were unable to neutralize LE-IFN-a entirely, even though they can neutralize several IFN-a subtypes. In addition, the results indi-
cate that a change to LE-IFN-a therapy can be associated with restoration of clinical responses in NAB-positive patients who had become
resistant after showing an initial response to PEG-IFN-a treatment. This study emphasizes the importance of evaluating NAB development
in CHC patients who become resistant to PEG-IFN-a treatment, and suggests management alternatives for patients who develop NAB.
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Introduction
Combination therapy using pegylated-interferon-a (PEG-IFN-
a) plus ribavirin (RBV) is currently the standard regimen for
patients with chronic hepatitis C (CHC) infection [1]. This
makes it possible to achieve a sustained virological response
in about 50% of cases of CHC, genotype 1b. Several factors,
including speciﬁc virus mutations, host factors (such as age,
gender, liver ﬁbrosis, lipid metabolism), and single nucleotide
polymorphism in, and expression of, some genes codifying
proteins involved in antiviral innate immunity, have been
reported as being associated with the therapeutic effects of
IFN [2–6]. A few studies explaining the failure of IFN-a ther-
apy have also been published in which the development of
neutralizing antibodies (NAB) against IFN-a in CHC patients
treated with PEG-IFN-a is described [7–9]. However, there
have been few reports relating to this issue and, although
there is abundant literature on the seroconversion rate dur-
ing recombinant IFN-a therapy, many issues relating to NAB
development in PEG-IFN-a therapy have yet to be addressed
[10].
Within the framework of a study aimed at further charac-
terizing the in vivo immunogenicity of PEG-IFN-a prepara-
tions, we aimed to assess the immunogenicity of PEG-IFN-a
preparations when administered to CHC patients who had
or had not received previous therapy with standard recombi-
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nant IFN-a products. In addition, the neutralizing speciﬁcities
of NAB, together with the ability of natural human IFN-a to
re-establish therapeutic responsiveness in non-responder
patients with CHC who develop anti-IFN NAB while being
treated with PEG-IFN-a, have been evaluated.
Materials and Methods
Patients
Analyses of NAB were performed on serum samples
collected from 179 patients with CHC who had been treated
with PEG-IFN-a 2a (Pegasys; Hoffmann-LaRoche, Basel,
Switzerland) or 2b (PegIntron; Schering-Plough, Kenilworth,
NJ, USA) plus RBV. The patients were divided into two
groups, depending on whether or not they had previously
received therapy with standard IFN-a preparations. Serum
samples were collected at the beginning of therapy and after
6 months, and were stored at )80C.
In addition, in this study attention focused on ﬁve NAB-
positive patients with CHC in whom treatment with PEG-
IFN-a had failed, and who therefore had to start a new cycle
of IFN therapy. To perform an evaluation of NAB speciﬁci-
ties, sera were collected from these patients before starting
leucocyte (LE) -IFN-a (Alfaferone; Alfa Wassermann, Bolo-
gna, Italy) plus RBV therapy and stored at )80C. In one
patient, serum samples were collected after 1, 2, 3, 4, 5 and
6 months of therapy.
Written informed consent was obtained from each patient
and the ethics committees of the participating institutions
approved the study.
Detection of NAB to IFN-a
Antibody titres were determined, as described previously, by
a neutralization test against 10 IU/mL of IFN-a [11,12]. Dif-
ferent IFN-a preparations were used: IFN-a 2a (Roferon;
Hoffman-La Roche); IFN-a 2b (Intron; Schering-Plough), LE-
IFN-a (Alfaferone; Alfa Wassermann); Multiferon (Swedish
Orphan Biovitrum, Stockholm, Sweden) and subtypes of IFN-
a (PBL Biomedical Laboratories, Piscataway, NJ, USA). Titres
were calculated using the Kawade method and expressed as
ten-fold reduction units (TRU/mL), that is, the dilution of
serum that reduces 10 IU/mL of IFN to 1 IU/mL [13–15].
Statistical methods
Seroconversion rates were compared using the chi-square
test. Two-group comparisons of means were done using
Student’s t-test. A simple logistic regression, after adjusting
for type of PEG-IFN-a administered and genotype of hepati-
tis C virus (HCV; genotype 1 versus other genotype) was
used to evaluate the degree of variables association
between treatment-experienced and IFN-a standard-naive
HCV-positive patients. A p-value <0.05 was considered sta-
tistically signiﬁcant. The analysis was performed using SPSS
version 13Æ0 for Windows.
Results
PEG-IFN-a immunogenicity
The rates of NAB production against IFN-a in patients with
CHC who had received PEG-IFN-a therapy exclusively were
compared with those of patients who had undergone
previous courses of therapy with standard IFN-a products
before starting PEG-IFN-a therapy. The demographic and
clinical characteristics of both groups of patients with CHC
are shown in Table 1. Of the patients with CHC treated
with PEG-IFN-a who had received no previous IFN-a
therapy, none had detectable levels of NAB before therapy,
and only one patient developed NAB to IFN-a 6 months
after starting PEG-IFN-a therapy. In contrast, NAB were
observed in 8% (4/52) of the CHC patients who had
received second-line treatment with PEG-IFN-a after
previous therapy with standard IFN-a preparations 6 months
after beginning PEG-IFN-a therapy. In one of these patients,
NAB positivity was recorded before PEG-IFN-a therapy had
started. The results shown in Fig. 1 indicate that the
incidence of NAB to IFN-a after 6 months of PEG-IFN-a
therapy was lower in patients treated exclusively with PEG-
IFN-a than in those who had received standard IFN-a
therapy before starting PEG-IFN-a treatment (p <0.05).
TABLE 1. Demographic and clinical characteristics of
patients with chronic hepatitis C who had received (Group
A) or not (Group B) a previous interferon-a (IFN-a) stan-
dard treatment before starting pegylated (PEG) -IFN-a plus
ribavirin therapy
Parameter
Group A
n = 52
Group B
n = 127 p valuea
Sex, male (%) 58 74 >0.05
Age, years (mean ± SD) 53 ± 10 48 ± 18 >0.05
Genotype (%)
1 82 45 <0.05
2 4 40 <0.05
3 6 13 >0.05
4 8 2 >0.05
Baseline hepatitis C viraemia,
log IU/mL (mean ± SD)
6.17 ± 6.54 5.97 ± 5.98 >0.05
Baseline alanine aminotransferase,
IU/L (mean ± SD)
127 ± 95 113 ± 86 >0.05
Type of IFN-a administered
PEG-IFN-a 2a (%) 67 19 <0.05
PEG-IFN-a 2b (%) 33 81 <0.05
aMeans and proportions were compared using Student’s t-test and chi-square
tests. The analysis was performed using SPSS version 13.0. for Windows.
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In addition, when all variables were included simulta-
neously in a multiple logistic regression analysis, after adjust-
ing for type of PEG-IFN-a administered and HCV genotype
(1b versus other), no signiﬁcant association was found
between any clinical and demographic parameters of the two
groups of HCV-positive patients. The only exception was the
observation that being not naive for IFN treatment was asso-
ciated with an increased risk of developing neutralizing anti-
bodies (OR 10.09, 95% CI 0.95–107.13) although this
increase was not signiﬁcant at the conventional level
(p 0.055).
Clinical and demographic characteristics of NAB-positive
patients are shown in Table 2. It can be seen that almost all
NAB-positive patients did not achieve a virologic response
to PEG-IFN-a therapy, as documented by measuring levels of
HCV RNA, which never dropped to undetectable levels.
However, we observed that a sustained virological response
was reached in only 32% of the NAB-negative patients who
had undergone previous courses of conventional IFN-a ther-
apy in contrast to the sustained virological response rate of
70% observed in IFN-a standard naive-HCV-positive patients
who did not develop NAB during PEG-IFN-a treatment.
NAB speciﬁcities
With the aim of investigating the development of NAB in
CHC patients further, our attention focused on another
group of ﬁve patients with CHC in whom treatment with
PEG-IFN-a preparations plus RBV had failed after an initial
virological response, and who therefore had to start a new
cycle of IFN therapy (Table 3). With the exception of patient
3, these patients had not received IFN-a standard therapy
previously. Treatment with PEG-IFN-a plus RBV was inter-
rupted after 3 (patient 3), 6 (patients 4 and 5), and 8 (patient
2) months, respectively, when they were found to have
developed NAB. In contrast, patient 1 relapsed after the ﬁrst
cycle of PEG-IFN-a 2b plus RBV therapy and NAB were
detected in serum collected from this patient after the inter-
ruption of a second cycle of antiviral therapy (9 months). All
patients started a new cycle of LE-IFN-a plus RBV (800–
1200 mg/day) therapy. To perform an evaluation of NAB
speciﬁcities, sera samples were collected from these patients
before starting treatment with LE-IFN-a plus RBV. Interest-
ingly, the levels of NAB produced during PEG-IFN-a therapy
varied greatly (coefﬁcient of variation > 100%; Table 3). The
ability of NAB developed during PEG-IFN-a therapy to neu-
tralize other preparations of IFN, such as LE-IFN-a, was then
evaluated (Table 3). In particular, no neutralizing activity
(<10 TRU/mL) against LE-IFN-a was recorded in sera with
an NAB titre of £107 TRU/mL against IFN-a 2. Otherwise,
sera with an NAB titre of ‡293 TRU/mL against IFN-a 2
were to some extent able to neutralize LE-IFN-a, even
though a much greater neutralizing activity against IFN-a 2
compared with that against LE-IFN-a was observed. Similar
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FIG. 1. Development of anti-interferon (IFN) neutralizing antibody
in patients with chronic hepatitis C (CHC). Analysis was performed
before (T0) and after 6 months (T6) of pegylayed (PEG) -IFN-a plus
ribavirin treatment in patients with CHC who had (white bars) or
had not (black bars) been treated previously with a conventional
IFN-based regimen. p <0.05 using the chi-square test.
TABLE 2. Demographic and clinical characteristics of patients with chronic hepatitis C who had developed neutralizing anti-
bodies
Pt Sex
Age
(years) G
HCV RNA (Log IU/mL)
ALT
(IU/mL)
Type
of PEG-IFN
Previous
IFN standard
therapy
NAB
(TRU/mL)
Type of
responseT0 T3 T6 T12 T0 T6
a F 39 1b 6.64 6.18 6.87 6.73 271 123 a 2a Yes 80 NR
b M 62 1b 4.26 <2 <2 <2 136 30 a 2a Yes 90 SVR
c F 60 1b 5.13 5.02 4.95 5.44 120 30 a 2a Yes 187 NR
d F 65 2 5.36 5.25 Positive 5.51 109 91 a 2b Yes 533 NR
e F 45 1b Positive Positive Positive Positive 40 35 a 2b No 50 NR
Pt, patient; G, genotype; T0, baseline; T3, T6, T12 after 3, 6, 12 months of pegylated interferon (PEG-IFN) therapy; IU, international unit; ALT, alanine aminotransferase;
NAB, neutralizing antibodies; TRU, tenfold reduction units; NR, no response; SVR, sustained virological response.
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results were obtained when the same sera were titrated
against Multiferon, a new preparation of natural IFN-a that
contains several naturally occurring IFN-a subtypes.
Having established that NAB-positive sera obtained from
non-responder patients treated with PEG-IFN-a failed to
completely neutralize the natural IFN-a preparations, we
next evaluated the speciﬁcity of such neutralizing activity
against IFN-a subtypes (Table 3). It can be seen that the titre
against IFN-a 2a or 2b, the IFN-a subtype originally adminis-
tered, was highest in most NAB-positive patients. Several
other IFN-a subtypes were neutralized by the same sera
whereas, in others, the antiviral activity was only marginally
affected.
Together, the results show that the inhibitory activity of
NAB was overcome by almost all IFN-a subtypes in sera that
failed to neutralize natural IFN-a preparations (<10 TRU/
mL). In contrast, many IFN-a subtypes were neutralized by
sera that, to some extent, neutralized natural IFN-a prepara-
tions (£627 TRU/mL), although in some cases antiviral activ-
ity was only marginally affected. Interestingly, all sera that
were positive for NAB against IFN-a 2 preparations cross-
reacted with the IFN-a 6 subtype, whereas other IFN-a sub-
types were neutralized only by sera that neutralized natural
IFN-a. The sole exception was IFN-a 5, which was also rec-
ognized in a serum collected from patient 2 that had failed
to neutralize natural IFN-a preparations.
The fate of NAB after changing to LE-IFN-a therapy
A recovery in clinical response after switching to LE-IFN-a
plus RBV was observed in patients 1, 2 and 5, independent
of the presence in their sera of NAB against natural IFN-a
preparations (Table 3). In contrast, patient 4, who had a
measurable NAB titre against natural IFN-a preparations, did
not respond to LE-IFN-a therapy.
In addition, we were able to evaluate the changes in NAB
speciﬁcities to IFN-a during LE-IFN-a treatment for patient
2. The results are shown in Fig. 2. It can be seen that over
6 months of LE-IFN-a therapy, no neutralizing activity against
natural IFN-a preparations was observed, nor were changes
seen in NAB speciﬁcities to almost all IFN-a subtypes, with
the exception of the development of NAB against the IFN-a
10 subtype. The NAB titre against some IFN-a subtypes also
showed a weak increase during LE-IFN-a therapy.
Discussion
The present study demonstrates, we believe for the ﬁrst time,
that patients with CHC who have received a previous course
of standard IFN-a treatment, have a greater probability ofT
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developing NAB after administration of PEG-IFN-a than
patients being treated for the ﬁrst time with this preparation.
This important ﬁnding suggests that the long-term admin-
istration of different types of chemical products with the
same IFN-a subtype could induce an immunological response
even towards PEG-IFN-a preparations, which have been
shown to possess lower immunogenicity compared with
those reported for the standard preparations of IFN-a [16–
18]. The seroconversion rate to PEG-IFN-a observed in our
study is also lower than those reported recently [9]. How-
ever, it should be noted that Halfon et al. [9] measured NAB
levels in sera collected from patients with CHC with an
ELISA test, which detects antibodies that bind several differ-
ent antigenic epitopes of the IFN-a molecule, some of which
are not involved in the activation of type I IFN receptors
and are recognized only by binding but not neutralizing anti-
bodies. In contrast, in our own analysis, we used a univer-
sally employed, quantitative, standardized virus-induced
cytopathic-effect assay based on IFN induction of antiviral
resistance, which is considered to represent the reference
standard for measurement of NAB [14].
This is the ﬁrst study in which NAB speciﬁcities produced
during PEG-IFN-a therapy have been analysed. It is of inter-
est that only sera with high NAB titres against the IFN-a 2
subtype had the ability to neutralize, even though to a lower
and different extent, most of the IFN-a subtypes, and, conse-
quently, natural IFN-a preparations. In contrast, only a few
subtypes of IFN-a were neutralized by those sera with low
titres of NAB against the IFN-a 2 subtype. The ability of
NAB that developed against IFN-a 2 to recognize other clo-
sely related type I IFN-a subtypes has also been reported in
patients with CHC, autoimmune diseases or tumours treated
with conventional IFN-a preparations [11,19–22].
Speciﬁcally, our results show that the IFN-a 6 subtype
was recognized by all sera positive for NAB to IFN-a 2,
whereas IFN-a 1 subtypes were only marginally neutralized.
In agreement with this, Nolte et al. [23] showed that NAB
that developed in patients suffering from leukaemia during
IFN-a 2 treatment, neutralized IFN-a 6 but not (or only mar-
ginally) IFN-a 1. The different IFN-a subtype speciﬁcities of
NAB produced during PEG-IFN-a therapy may be explained
by the observation that some amino acids within residues
17–65 of the N-terminal functional domain of the IFN-a 2
subtype, recognized by neutralizing therapy-induced NAB,
are identical in IFN-a 2 and IFN-a 6 subtypes but different in
IFN-a 1 [23].
As far as the clinical impact of NAB developed during
PEG-IFN-a treatment is concerned, our results conﬁrm that
the development of NAB may be one of the host factors
associated with the lack of clinical response to IFN-a therapy
[7,8,11,18,24–26]. This seems particularly evident for the
group of HCV-positive patients who became resistant to
PEG-IFN-a treatment concomitantly with the development
of anti IFN neutralizing antibodies and who therefore had to
start a new cycle of LE-IFN-a therapy. However, a lack of vi-
rological response after 3 months of PEG-IFN-a therapy was
observed in most IFN-a standard treatment-experienced
NAB-positive patients. In addition, the rate of sustained viro-
logical response was also low in NAB-negative patients who
underwent a second course of IFN therapy with a PEG-IFN-
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FIG. 2. Speciﬁcities of anti-interferon (IFN) neutralizing antibody during leucocyte (LE) -IFN-a therapy. Serum samples were collected from
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a preparation. This ﬁnding seems to be expected considering
that most patients who previously had no response to stan-
dard IFN therapy independently of their NAB status were
infected with HCV genotype 1, which is known to show a
worse treatment response compared with the other HCV
genotypes.
In addition, one patient, who had received a previous con-
ventional IFN-a preparation, showed a positive clinical
response to PEG-IFN-a therapy, despite the presence of
NAB. Achievement of a sustained virological response
despite the presence of NAB could be explained in this case
by hypothesizing that this patient developed NAB after the
decline in HCV-RNA to undetectable levels observed in the
ﬁrst few months of therapy. This ﬁnding is not surprising and
does not seem to be conﬁned solely to HCV-positive
patients. Indeed, it has been reported that NAB cannot affect
the clinical efﬁcacy of IFN-b treatment in certain patients
with multiple sclerosis who clinically responded to IFN
before the occurrence of seroconversion [27].
These observations indirectly emphasize the complexity of
the phenomenon analysed and the difﬁculty in interpreting
the data on the evaluation of the inﬂuence of NAB develop-
ment in the outcome of PEG-IFN-a therapy in patients with
CHC.
Furthermore, and more importantly from a practical view-
point, our results indicate that a second course of treatment
with the natural IFN preparation may be useful in most anti-
interferon NAB-positive patients who fail to respond to
PEG-IFN-a plus RBV therapy as previously described
[8,28,29].
A recovery in clinical response to natural IFN-a was also
observed in one patient who had NAB against virtually all
IFN-a subtypes before starting LE-IFN-a plus RBV therapy.
This ﬁnding may suggest that some IFN-a subtypes present
in the mixture of the natural IFN-a preparation, which were
neutralized to a low extent, might still exert their biological
activity in patients with CHC as reported by others
[8,10,11]. Nonetheless, we consider that the observation
that natural IFN-a preparation could induce a widening of
NAB speciﬁcities to IFN-a subtypes should be taken into
consideration in the clinical management of patients who, as
non-responders to PEG-IFN-a therapy, have developed NAB
and who can be successfully re-treated with different IFN-a
preparations or with new anti-HCV drugs.
In conclusion, our data show that PEG-IFN-a prepara-
tions possess an immunogenic potential when administered
to CHC patients who have previously received conventional
IFN-a therapy. Our data also indicate that NAB that devel-
oped in patients with CHC during PEG-IFN therapy are not
able to neutralize natural IFN-a entirely, even though they
possess a broad speciﬁcity of neutralizing activity. In addi-
tion, our data suggest that the presence of NAB to individ-
ual IFN-a species will not signiﬁcantly diminish the clinical
efﬁcacy of natural IFN-a preparations. Given the impact of
NAB on clinical response to PEG-IFN-a therapy, our results
taken as a whole underline the importance of evaluating
NAB production, in patients who have become resistant
after showing an initial response to PEG-IFN-a treatment
and have undergone previous therapy with standard IFN-a,
to provide therapeutic alternatives for managing NAB-posi-
tive patients.
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